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Abstract We found that ticlopidine, at therapeutically relevant
concentrations (2.5^10 WM), but not aspirin nor salicylate,
significantly counteracted copper-driven human LDL oxidation.
Ticlopidine, at 5 and 10 WM, was also antioxidant on peroxyl
radical-induced LDL oxidation; yet it was ineffectual on thiol
and ascorbate oxidation mediated by peroxyl radicals them-
selves, suggesting that drug antioxidant capacity is somehow
related to the lipoprotein nature of the oxidizable substrate, but
not to radical scavenging. The drug could not indeed react with
the stable free radical 1,1-diphenyl-2-pycrylhydrazyl, nor had
apparent metal complexing-inactivating activity. Thus, ticlopi-
dine has antioxidant effects on LDL oxidation, which, together
with its anti-platelet activity, could confer peculiar antiathero-
genic properties to the drug in vivo.
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1. Introduction
In recent years evidence has accumulated indicating that
oxidized low-density lipoproteins (LDL) play a central role
in atherogenic processes and that LDL oxidation can be pre-
vented by antioxidant compounds [1^3].
Some antioxidants seem to exert speci¢c e¡ects on LDL or
other lipid system oxidation as a consequence of their lipo-
philicity, resulting in a less lipid propensity to undergo radi-
cal-driven oxidant damage [4^9]. Ticlopidine, a widely used
anti-platelet agent with a proven clinical e⁄ciency [10^12], is
a thienopyridine characterized by lipophilic properties (Fig.
1); the drug is indeed strictly associated with the lipid moiety
of human lipoproteins, such as LDL [13]. Moreover, the pres-
ence of sulfur in the chemical structure of ticlopidine (Fig. 1)
might also suggest some scavenging activity of the drug
against radical species involved in lipid and LDL oxidation,
such as peroxyl radicals, as reported by Pryor and associates
for probucol [14]. Thus, some antioxidant activity of ticlopi-
dine on LDL oxidation may be hypothesized.
The present study was designed to investigate possible anti-
oxidant properties of ticlopidine on human LDL oxidation.
For comparison, the e¡ects of another well known anti-plate-
let drug, namely aspirin, and of its main metabolite salicylate,
were also studied. The results show that ticlopidine only is
capable of inhibiting LDL oxidation in speci¢c model sys-
tems, this e¡ect being evident at therapeutically achievable
concentrations.
2. Materials and methods
2.1. LDL isolation and oxidation
Reagents were from Sigma Aldrich, Milano, Italy, except for 2,2P-
azobis(amidinopropane) dihydrochloride (AAPH), which was from
Polysciences, Warrington, USA. LDL were isolated from EDTA plas-
ma of healthy subjects (age 26^52 years) by density gradient ultra-
centrifugation at 4‡C essentially as reported by Frei and Gaziano [15].
After puncture aspiration of the LDL band, samples were extensively
dialyzed against phosphate bu¡ered saline (PBS), pH 7.4, at 4‡C.
Drugs were used at therapeutically relevant ¢nal concentrations,
namely 2.5, 5 and 10 WM for ticlopidine, and up to 100 and 200 WM
for aspirin and sodium salicylate, respectively [16^18].
Drug capability to inhibit copper-mediated LDL oxidation was
evaluated in quartz cuvettes through continuous spectrophotometric
monitoring of absorbance increase at 234 nm, re£ecting conjugated
dienes (CD) formation during peroxidative processes [19,20]. In this
regard, a kinetic study of the duration of the lag phase, of the rate of
CD production and of the maximal yield of CD generation was spe-
ci¢cally performed [19,20]. Oxidation of LDL (0.1 mg LDL protein/
ml) was induced by 5 WM CuSO4 in PBS, pH 7.4, with and without
the drugs, using appropriate LDL- and drug-containing blanks. Re-
sults were calculated as nmol CD/mg LDL protein, using a molar
extinction coe⁄cient of 29 500 at 234 nm [19,20]. In some experiments,
drug e¡ects on copper-catalysed LDL oxidation were assessed meas-
uring aldehydic by-products of lipoperoxidation through a thiobarbi-
turic acid (TBA) test, after 2 h incubation at 37‡C of LDL (0.1 mg
LDL protein/ml) with 5 WM CuSO4 in PBS, pH 7.4. TBA reactive
substances (TBARS) were assayed basically according to Ohkawa et
al. [21], with some modi¢cations [22]. Brie£y, a suitable aliquot of the
LDL sample was added to a reaction mixture containing 0.25 mM
EDTA, 20 WM butylated hydroxytoluene in absolute ethanol, 0.1 ml
of 8.1% sodium dodecyl sulfate, 1.3 ml of 20% acetic acid, pH 3.5, and
1.3 ml aqueous solution of 0.6% TBA, followed by 30 min heating at
95‡C. After cooling and centrifugation, the chromogen was read at
532 against an appropriate blank. Results were calculated as nmol
TBARS/mg LDL protein, using a molar extinction coe⁄cient of
154 000. No pharmacological interference was observed in the TBA-
test.
When a drug was found to a¡ord protection against copper-medi-
ated LDL oxidation, further investigations were speci¢cally performed
to examine the mechanisms involved in drug antioxidant protection
(see below).
In other speci¢c experiments, therefore, the oxidation of LDL
(0.1 mg LDL protein/ml) was induced in a metal-independent fashion
through the peroxyl radical-generating azo-initiator AAPH (4 mM) in
the presence of 0.1 mM diethylenetriaminepentaacetic acid (DTPA)
[15], allowing 3 h incubation at 37‡C in PBS, pH 7.4. LDL oxidation
was assessed through the TBA-test, as reported above.
LDL-protein was measured by the method of Lowry et al. [23].
2.2. Drug radical scavenging activity
Drug capability to inhibit AAPH-mediated, peroxyl radical-induced
oxidation of di¡erent non-lipid substrates, namely the thiol compound
5-thio-2-nitrobenzoic acid (TNB) and ascorbic acid, was investigated.
TNB was prepared through reduction of 5,5P-dithiobis(2-nitrobenzoic
acid) with 2-mercaptoethanol as reported by Thomas et al. [24], and
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its concentrations were calculated using a molar extinction coe⁄cient
of 13 600 at 412 nm [24]. Reaction mixtures contained 37 WM TNB,
0.1 mM DTPA and 4 mM AAPH, with or without various drug
concentrations, in PBS, pH 7.4. Incubation was for 3 h at 37‡C.
Absorbance values at 412 nm (A412) were then recorded spectrophoto-
metrically against appropriate blanks to detect speci¢c drug e¡ects.
For ascorbate oxidation, reaction mixtures contained 55 WM ascorbic
acid and 8 mM AAPH, with and without ticlopidine, in pyrogen-free
physiological saline, where the vitamin is quite stable and virtually
does not autooxidize. After 90 min incubation at 37‡C, ascorbate-
related absorbance values at 265 nm were recorded spectrophotomet-
rically against appropriate blanks. Results were calculated as nmol
ascorbic acid oxidized/ml/min, using a molar extinction coe⁄cient of
15 000.
We also evaluated drug capacity to interact with and scavenge the
stable free radical 1,1-diphenyl-2-pycrylhydrazyl (DPH), inducing 1,1-
diphenyl-2-picrylhydrazine formation and DPH bleaching [25,26]. It
should be noted that reaction with DPH is typical of those substances
acting as antioxidants by virtue of their radical scavenging properties
[25,26]. The reaction system contained 90 WM DPH (previously dis-
solved in ethanol) in PBS, pH 7.4, with or without various drug
concentrations. In some experiments, the reaction was carried out
directly in organic solvents, such as ethanol or chloroform. After
5 min incubation at 25‡C, DPH-related absorbance values at 517
(A517) were recorded spectrophotometrically against appropriate
drug-containing blanks.
2.3. Drug-copper interaction
Possible drug interactions with copper were investigated through an
ultraviolet spectral study (from 270 to 200 nm) of ticlopidine with
either copper(II) as CuSO4 in PBS, or copper(I) as CuCl in argon-
purged acetonitrile. To further study drug-copper interaction, £uores-
cence-quenching experiments were speci¢cally carried out for ticlopi-
dine, which shows an intrinsic £uorescence. Indeed, the relative £uo-
rescence of a substance can be quenched by catalytic transition metals,
as a result of formation of a complex between such a substance and
metals themselves [22,27]. Excitation and emission wavelengths of
ticlopidine were determined to be 321 and 435 nm; the drug was
used at a ¢nal concentration of 10 WM, while the concentrations of
CuSO4 (which gave no interference at the afore-mentioned wave-
lengths) ranged from 1.0 to 100 WM. Finally, drug e¡ects on cop-
per-induced ascorbic acid oxidation were investigated [28]. Reaction
mixtures contained 37 WM ascorbic acid and 5 WM CuSO4, with and
without ticlopidine, in pyrogen-free physiological saline. After 15 min
incubation at 37‡C, ascorbate-related absorbance values at 265 nm
were recorded spectrophotometrically against appropriate drug-con-
taining blanks. Results were calculated as nmol ascorbic acid oxi-
dized/ml/min.
2.4. Statistics
Data were calculated as means þ S.D. of 7 di¡erent experiments,
unless otherwise indicated. Speci¢c drug e¡ects were evaluated by
the one-way analysis of variance (ANOVA) plus Student-Newman-
Keuls test [29]. P6 0.05 was regarded as statistically signi¢cant.
3. Results
3.1. Drug e¡ects on LDL oxidation
As shown in Table 1 and in Fig. 2, ticlopidine signi¢cantly
in£uenced the kinetics of copper-driven LDL oxidation. In-
deed, lag time was prolonged in a dose-dependent fashion by
ticlopidine, resulting about 1.5-, 2.3- and 4-fold longer than
that of control at 2.5, 5 and 10 WM drug concentrations,
respectively (Table 1). Moreover, oxidation rate and maximal
yield of CD production were decreased by ticlopidine, a sig-
ni¢cant e¡ect being evident, however, beginning from 5 WM
drug concentration (Table 1). In the same experimental con-
ditions, either aspirin or salicylate were ine¡ective (data not
shown). When copper-catalyzed LDL oxidation was evaluated
through TBARS assay, 67 þ 9.5 nmol TBARS/mg LDL pro-
tein were generated in control experiments; TBARS were in-
stead 58.5 þ 11 and 33 þ 7.5 nmol/mg LDL protein in the pres-
ence of 2.5 and 5 WM ticlopidine (P6 0.05; n = 6), and they
were virtually undetectable with 10 WM ticlopidine, further
indicating an e¡ective antioxidant activity of the drug.
Moreover, ticlopidine, at 5 and 10 WM concentrations, sig-
ni¢cantly counteracted AAPH-mediated, peroxyl radical-in-
duced LDL oxidation, which resulted in 38.2 þ 4.7 nmol
TBARS/mg LDL protein in control experiments, as compared
to 34.4 þ 4.1, 28.7 þ 2.8 and 26 þ 3.1 nmol TBARS/mg LDL
protein with 2.5, 5 and 10 WM drug concentrations, respec-
tively (5 and 10 WM ticlopidine vs. control, P6 0.05; n = 5).
3.2. Drug radical scavenging activity
To investigate whether the antioxidant activity of ticlopi-
dine on peroxyl radical- and copper-induced LDL oxidation
could be related to its direct radical scavenging properties or
to the lipoprotein nature of the oxidizable substrate, we as-
sessed drug e¡ects on AAPH-mediated, peroxyl radical-in-
duced oxidation of the non-lipid compounds TNB and ascor-
bic acid. Ticlopidine was incapable of inhibiting such
oxidations; in fact, incubation with AAPH resulted in a
marked decrement of TNB-related A412 values (from
0.502 þ 0.032 to 0.037 þ 0.006, n = 5), and ticlopidine, even at
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Fig. 1. Chemical structure of ticlopidine.
Table 1
E¡ect of ticlopidine on the kinetics of copper-mediated human LDL
oxidation
Lag time (min)
Control 48.7 þ 6.2
Control plus ticlopidine:
2.5 WM 77.15 þ 7.4*
5 WM 112.4 þ 17.3*;**
10 WM 200.8 þ 30*;**
Oxidation rate (nmol CD/min/mg
LDL protein)
Control 2.8 þ 2.4
Control plus ticlopidine:
2.5 WM 11.8 þ 1.9
5 WM 9.7 þ 1.7*;***
10 WM 8.35 þ 1.4*;***
Maximal CD production
(nmol CD/mg LDL protein)
Control 402.4 þ 32.5
Control plus ticlopidine:
2.5 WM 385.6 þ 30
5 WM 347.3 þ 31.5*;***
10 WM 333.7 þ 25*;***
Means þ S.D. of 7 di¡erent experiments. CD: conjugated dienes.
*P6 0.05 vs. control; **P6 0.05 vs. preceding values; ***P6 0.05
vs. 2.5 WM ticlopidine (ANOVA plus Student-Newman-Keuls test).
See Sections 2 and 3 for further methodological explanations.
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10 WM, was ine¡ective (0.035 þ 0.005 A412, P = NS; n = 5).
Moreover, 0.42 þ 0.027 nmol/ml/min ascorbic acid were oxi-
dized by AAPH-generated peroxyl radicals, not di¡erent from
the values detected with 10 WM ticlopidine (0.43 þ 0.023 nmol/
ml/min, P = NS; n = 5). In line with these experiments, ticlo-
pidine could not interact with the stable free radical DPH,
further suggesting no direct radical scavenging activity of
the drug [25,26]. DPH-related A517 values were indeed
0.603 þ 0.030 in control experiments, not signi¢cantly di¡erent
from those observed with 10 WM ticlopidine (0.608 þ 0.035,
P = NS; n = 5). Similarly, the drug was ine¡ective when the
reaction was carried out in organic solvents (not shown).
Overall, these data indicate that the speci¢c antioxidant
e¡ects of ticlopidine are apparently related to the (lipid) na-
ture of the oxidizable substrate, namely LDL, and not to a
direct radical scavenging activity of the drug.
3.3. Drug-copper interaction
Ticlopidine had no apparent copper-binding e¡ect, as
judged by both spectral study and lack of quenching of the
intrinsic drug £uorescence by copper (not shown). Further-
more, the drug did not in£uence copper-driven ascorbate ox-
idation, suggesting that the metal redox potential and cata-
lytic activity is substantially una¡ected by the drug [28].
Indeed, 0.78 þ 0.1 and 0.8 þ 0.08 nmol/ml/min of ascorbic
acid were oxidized by copper with and without 10 WM ticlo-
pidine, respectively (P = NS; n = 5).
4. Discussion
The present study shows that ticlopidine, but not aspirin or
salicylate, can inhibit human LDL oxidation. Three mecha-
nisms should be basically considered in the pharmacological
antagonism of copper-mediated LDL oxidation: (i) metal
complexation-inactivation; (ii) scavenging of radical species
involved in LDL oxidation, such as peroxyl, alkoxyl or lipid
radicals ; (iii) stabilization of the lipid moiety of LDL, con-
ceivably via chemical interactions between drug hydrophobic
groups and polyunsaturated residues of LDL phospholipids.
Our data indicate no speci¢c antioxidant e¡ects of ticlopidine
as a result of copper complexation-inactivation. Even though
the antioxidant activity of ticlopidine on AAPH-mediated
LDL oxidation may suggest drug scavenging properties
against peroxyl radicals, other experimental data herewith re-
ported do not point to a similar mechanism. Indeed, ticlopi-
dine is ine¡ective on the oxidation of the non-lipid com-
pounds TNB and ascorbate mediated by AAPH, and it does
not interact with the stable free radical DPH. Regarding
AAPH, it seems to form an equilibrium between the lipid
and aqueous environment, with peroxyl radicals being gener-
ated in both phases [30] ; thus, it is possible that a lipophilic
drug capable of stabilizing LDL phospholipids could a¡ord
some protection against AAPH-mediated LDL oxidation. It
cannot be totally excluded, however, that ticlopidine might
speci¢cally interact with some (lipid) radicals generated during
copper-catalysed oxidative processes directly within the hy-
drophobic core of LDL. Given the lipophilic nature of ticlo-
pidine and its capacity to bind to lipids in LDL [13], the
antioxidant properties of the drug may be directly related to
a stabilization of the phospholipid moiety of LDL with de-
creased lipid propensity to undergo radical-driven oxidant
damage. Consistent with this, it has recently been reported
that the 3-hydroxy-3-methylglutaryl coenzyme A inhibitor £u-
vastatin can inhibit both copper and AAPH-mediated LDL
oxidation apparently as a result of drug binding to LDL
phospholipids with prevention of radical di¡usion into the
lipoprotein core [31]. Moreover, lipophilic drugs, such as phe-
nothiazines, calcium antagonists, beta-blockers and tamoxi-
fen, are known to exert inhibitory e¡ects on LDL oxidation
[4,6,8,9]. Indeed, the role of the physical state of the lipid
phase in the susceptibility of lipids to peroxidative processes
has been pointed out [32,33].
Plasma peak concentrations of ticlopidine are up to 7 WM
after drug administration of 500 mg/day in young volunteers,
and ticlopidine plasma levels are in elderly patients twice
those found in young men [16,17]; however, far higher con-
centrations may be expected in the lipoprotein compartment,
where the drug is bound [13]. Thus, the antioxidant activity
of ticlopidine on LDL oxidation is evident at therapeutic
concentrations and appears feasible in the clinical setting. A
lipophilic antioxidant strictly associated with LDL may delay
LDL oxidation especially in the vascular wall and thus the
development of atherosclerosis. Evidence for the relevance
of extending the lag time for LDL oxidation is provided by
clinical studies indicating an inverse relationship between the
duration of such lag time and the severity of atherosclerosis
[34]. The e⁄cacy of ticlopidine in the prevention of athero-
sclerosis-related cardiovascular diseases has been recognized
[10^12], and the drug has been reported to be even superior
to aspirin in speci¢c studies [10^12]. The previously unrecog-
nized antioxidant e¡ects of ticlopidine on LDL oxidation,
together with its well-known anti-platelet activity, could
confer peculiar antiatherogenic properties to the drug in
vivo.
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Fig. 2. Antioxidant activity of ticlopidine on human LDL oxidation.
Incubation of LDL was at 37‡C in PBS, pH 7.4, with 5 WM CuSO4
in the absence (trace A, control) or presence of 2.5, 5 and 10 WM
ticlopidine (traces B, C and D, respectively). Conjugated diene for-
mation during oxidation was followed spectrophotometrically in
quartz cuvettes as an increase of absorbance at 234 nm (ABS 234
nm). Figure represents results from a typical kinetic experiment (see
Sections 2 and 3 for further explanation).
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